NEWS

NEWS

Company News

Industry News

2025-10-29

Yichang Tianrui Biopharm Showcases Specialty API and CDMO Expertise at Jinan Pharma Partnering Forum

Yichang Tianrui Biopharm Showcases Specialty API and CDMO Expertise at Jinan Pharma Partnering Forum
YICHANG, China – October 20, 2025 – Yichang Tianrui Biopharm Co., Ltd., a wholly-owned subsidiary of Humanwell Group, successfully exhibited at the prestigious Jinan Pharma Partnering Forum, held at the Sheraton Jinan Hotel on October 16-17, 2025.

MORE

2025-10-20

Strengthening the Safety Lifeline, Forging "Robust" Emergency Response Capabilities—Tianrui Pharmaceutical's Labor Competition Concludes Successfully

Strengthening the Safety Lifeline, Forging "Robust" Emergency Response Capabilities—Tianrui Pharmaceutical's Labor Competition Concludes Successfully

MORE

2025-09-17

Yichang Renfu Pharmaceutical's Flurbiprofen Axetil Injection Receives Marketing Approval

Yichang Renfu Pharmaceutical's Flurbiprofen Axetil Injection Receives Marketing Approval

MORE

Yichang Renfu Pharmaceutical's Remimazolam Tosylate for Injection Receives Approval for New Indication

Yichang Renfu Pharmaceutical's Remimazolam Tosylate for Injection Receives Approval for New Indication

Yichang Renfu Pharmaceutical has received the Drug Registration Certificate for Remimazolam Besylate for Injection issued by the National Medical Products Administration, approving the addition of a new indication for this product: "Used as a sedative for sedation during mechanical ventilation in intensive care."

05

2025/09

Yichang Renfu Pharmaceutical's heavy tartrate norepinephrine injection approved for market launch

Yichang Renfu Pharmaceutical's heavy tartrate norepinephrine injection approved for market launch

Recently, the parent company Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for the heavy tartrate norepinephrine injection approved and issued by the National Medical Products Administration. This product was approved for market launch as a Category 3 chemical drug, with a specification of 4ml:8mg, and is considered to have passed the consistency evaluation.

04

2025/09

Moment of glory! Renfu Tianrui Pharmaceutical showcased at the 2025 Suzhou CMC Conference, winning two awards

Moment of glory! Renfu Tianrui Pharmaceutical showcased at the 2025 Suzhou CMC Conference, winning two awards

06

2025/08

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

01

2025/08

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for its rivastigmine transdermal patch from the National Medical Products Administration.

24

2025/07

Yichang Renfu Pharmaceutical's midazolam injection has been approved in France

Yichang Renfu Pharmaceutical's midazolam injection has been approved in France

Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a marketing authorization approval letter for midazolam injection from the French National Agency for the Safety of Medicines and Health Products (ANSM).

16

2025/07

Facing the future, a two-way rush to promote the better and faster development of the pharmaceutical and health industry | Stone Dai, General Manager of China Merchants Group, investigates Renfu Pharmaceutical Group

Facing the future, a two-way rush to promote the better and faster development of the pharmaceutical and health industry | Stone Dai, General Manager of China Merchants Group, investigates Renfu Pharmaceutical Group

On June 12, Shi Dai, General Manager of China Merchants Group, conducted a field research on Renfu Pharmaceutical Group in Yichang, listened to a briefing, conducted an on-site inspection of its core subsidiary, Yichang Renfu, and gave important work instructions. Wu Bo, Chief Accountant of China Merchants Group; relevant department heads of China Merchants Group; and representatives from related enterprises including China Merchants New Materials, China Merchants Bank, China Changjiang Navigation, China Merchants Transportation, and China Merchants Shekou participated in the research.

19

2025/06

Yichang Humanwell Pharmaceutical's Class 1 new drug RFUS-949 tablets approved for clinical trials

Yichang Humanwell Pharmaceutical's Class 1 new drug RFUS-949 tablets approved for clinical trials

Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the clinical trial of RFUS-949 tablets for the treatment of acute and chronic pain. This product is a new molecular entity drug developed by Yichang Renfu, classified as Class 1 chemical drug for registration, and there are no similar products approved for marketing in China.

06

2025/06